Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

d without deletion 17p
Session: 642. CLL: Therapy, excluding Transplantation: Clinical Trials of B Cell Receptor Signaling Inhibitors
Date: Monday, December 9, 2013
Presentation Time: 4:30 PM
Location: Ernest N. Morial Convention Center, 295-296
Presenter: Farooqui

Title: Ibrutinib inhibits B-cell adhesion and causes an efflux of chronic lymphocytic leukemia cells from the tissue microenvironment into the blood leading to a transient treatment-induced lymphocytosis
Session: 642. CLL: Therapy, excluding Transplantation
Date: Monday, December 9, 2013
Presentation Time: 4:45 PM
Presenter: Mustafa

Title: Effective inhibition of tumor microenvironment interactions in CLL patients treated with the BTK inhibitor ibrutinib result in sustained inhibition of tumor proliferation and survival pathways
Session: 641. CLL: Biology and Pathophysiology, excluding Therapy
Date: Sunday, December 8, 2013
Presentation Time: 5:45 PM
Location: Ernest N. Morial Convention Center, 288-290
Presenter: Herman

Title: In-vivo effects of ibrutinib on the migration of chronic lymphocytic leukemia cells differ between patients and reduce the ability of the bone marrow microenvironment to attract the tumor cells
Session: 604. Molecular Pharmacology, Drug Resistance
Date: Monday, December 9, 2013
Presentation Time: 5:15 PM
Location: Ernest N. Morial Convention Center, 275-277
Presenter: Herman

Non Hodgkin Lymphoma Oral Presentations:Title: Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study in Patients With CD20-Positive B-Cell non-Hodgkin's lymphoma
Session: 624. Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Aggressive Lymphomas
Date: Tuesday, December 10, 2013
Presentation Time: 8:45 AM
Location: Ernest N. Morial Convention Center, La Nouvelle Ballroom AB
Presenter: Younes

Wald
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... NORTHRIDGE, Calif. , March 30, 2015  The ... viable agent to alleviate certain menopause symptoms, such as ... the March Journal of Women,s Health .[i] ... with S- equol for menopausal vasomotor symptoms and ... studies supporting safety of S- equol, physicians and ...
(Date:3/30/2015)... 30, 2015  Building on the momentum of the first ... of medical alert systems, has announced aggressive plans to expand ... and Managed Care business models. The first quarter ... Tennessee and Louisiana ... contracts to span statewide coverage in each state. This brings ...
(Date:3/30/2015)... March 30, 2015 Perrigo Company plc (NYSE: ... "Quality Affordable Healthcare Products®," today announced that it has ... ("Omega") in a cash and equity transaction valued at ... billion in debt. Sellers are Marc Coucke , ... Waterland.    "The combination of ...
Breaking Medicine Technology:New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 2New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 3New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 5New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 6MedScope's Aggressive 2015 Expansion Focuses on Medicaid Waiver and Managed Care Organizations 2Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 2Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 3Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 4Perrigo Company plc Completes Acquisition Of Omega Pharma Invest N.V., Creating A Top Five Global OTC Company 5
... Tibotec Therapeutics, a division of Centocor Ortho Biotech ... and Drug Administration (FDA) has approved a revision ... of PREZISTA® (darunavir) tablets in combination with ritonavir ... in treatment-experienced adult patients with no darunavir resistance-associated ...
... OAKS, Calif., Dec. 13, 3010 Amgen (Nasdaq: ... Phase 3 trial evaluating XGEVA™ (denosumab) versus placebo in ... as the ,147 study, demonstrated that XGEVA significantly improved ... percent CI 0.73-0.98, p=0.03) compared to placebo (primary endpoint), ...
Cached Medicine Technology:FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations 2FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations 3FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations 4FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations 5FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations 6XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 2XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 3XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 4XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 5XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 6XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 7
(Date:3/30/2015)... Join local United Methodists as they Rethink Church ... to provide healthcare for the 512 students at Raise ... on Saturday, April 18, at 9 a.m. at Edwin ... Road in Nashville. , Raise the Roof Academy in ... medical care. The nearest clinic is a three-hour walk. ...
(Date:3/30/2015)... The pharmaceutical business has a global ... plants. This is primarily due to the decade-long merger/acquisition ... forced facilities to produce and perform well beyond their ... been forced to expand production, change product portfolios and ... Most of these facilities have remained in a poor ...
(Date:3/30/2015)... 30, 2015 With the summer dry ... areas are scrambling to make sure they have enough ... to be aware that when Earth loses water and ... and become dehydrated. Kleyne calls this “body drought” and ... talked about weather, body drought and dehydration on her ...
(Date:3/30/2015)... Murfreesboro, TN (PRWEB) March 30, 2015 Dr. ... TN office. , The mini implant is placed into ... to be stabilized is fitted and snapped into place. For ... or talking, mini implants could be the solution. Thousands of ... right in place without any adhesives. It is all made ...
(Date:3/30/2015)... Boca Raton, FL (PRWEB) March 30, 2015 ... organization which provides vascular, echocardiogram and ... recognize all national affiliated physicians in observance of National ... and every day around our office, but on this ... country for the important role they play in healing ...
Breaking Medicine News(10 mins):Health News:Hike2Heal and Rethink Church Raise Funds To Provide Healthcare for Ugandan Children with 3rd Annual Raise the Roof 5K on April 18 2Health News:FDAnews Announces: Aging Aseptic and Biological Manufacturing Facilities: Design and Renovation for Compliance Webinar, April 16, 2015 2Health News:FDAnews Announces: Aging Aseptic and Biological Manufacturing Facilities: Design and Renovation for Compliance Webinar, April 16, 2015 3Health News:As California Dry Season Approaches, Risk of Body Drought Increases, Warns Fresh Water Advocate 2Health News:As California Dry Season Approaches, Risk of Body Drought Increases, Warns Fresh Water Advocate 3Health News:Dr. Jeffrey Farmer A Murfreesboro Dentist Announces New High Tech Dentistry 2Health News:Wimbledon Health Partners Recognizes National Doctors’ Day 2
... provider,// has joined hands with Hayel Saeed Anam Group (HSA) ... Yemen. ,The two groups signed the partnership ... said a statement by Apollo Group here. ,Shawki ... honorary deputy governor of Taiz State in Yemen and Prathap ...
... treatment to quit smoking are significantly more likely to ... suggests that high-risk smokers with acute cardiovascular disease are ... intensive smoking cessation program. ,“Smoking is the ... author Syed M. Mohiuddin, MD, FCCP, Creighton University Cardiac ...
... that young men who have never been traumatized are the ... sexual abuse. ,The study – published in the ... also finds that males with high sexism beliefs also tend ... were not harmful to the victim. ,Some 80,000 ...
... (CDC)’s Morbidity and Mortality Weekly Report, West Virginia has a ... the U.S. Virgin Islands has the lowest. ... data collected through the Behavioral Risk Factor Surveillance System, a ... health departments. ,Levels of coronary heart disease, ...
... a favorable verdict in a case filed against the company ... Helen Rush of Little Rock.// ,According to Rush, ... had caused breast cancer in her. But the lawyers representing ... smoking would anyway have led her to the disease irrespective ...
... conference will present data that predict 17 percent of ... suffer from permanent hearing// loss. His data also show, ... is more hazardous to the ear when a car’s ... the results that will be presented by auditory physiologist ...
Cached Medicine News:Health News:Intense Cessation Treatment Proves Successful in High-Risk Smokers 2Health News:Never-Betrayed Men Less Likely to Indulge in Child Sex Abuse 2Health News:Never-Betrayed Men Less Likely to Indulge in Child Sex Abuse 3Health News:Car Airbags Will Cause Permanent Hearing Loss in 17 Percent 2
Bimod, acetabular cup "Xl" UHMWHDPE....
Metal on metal hip acetabular cups available for both cemented and cementless applications, the Biomet Merck metal on metal articulation hip system (M2aTM) combines proven materials with the latest i...
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Duraloc acetabular cup system....
Medicine Products: